ACTU Actuate Therapeutics, Inc.
$0.40▼ -24.32%
Healthcare
Other
After hours
$0.40▼ -0.13%
Oct 27, 5:52 PM ET
Volume 2.19M
Avg Volume (10D) 474.6K
Key Metrics & Fundamentals
Market Cap
$9.59M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.35 - 7.90
% vs 50 MA
-57.76%
% vs 200 MA
-82.13%
RSI-14
34.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.64
Free Cash Flow
-$4.41M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.86M
COGS
–
Operating Exp
$4.91M
Operating Income
-$4.91M
EBIT
-$4.91M
Pretax Income
-$4.87M
Net Income
-$4.87M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
GlobeNewswire · Oct 27, 2026 8:00 AM ET
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Zacks · Oct 12, 2026 11:07 AM ET
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
Zacks · Oct 8, 2026 10:47 AM ET
Top Premarket Decliners
MT Newswires · Oct 7, 2026 7:38 AM ET
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 9, 2026 5:00 PM ET
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
GlobeNewswire · Sep 9, 2026 7:00 AM ET
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy
Zacks · Sep 2, 2026 12:00 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ACTU's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.